Recomendaciones sobre el uso de palivizumab. Actualización 2015

Fetoneonatales, Comité de Estudios; S, Fernández Jonusas; D, Albas Maubett; Satragno, Daniela; Cattaino, Adriana; M, Martin Alonso; Nieto, Romina; Cardiología, Comité de; Neumonología, Comité de; Infectología, Comité de; Epidemiología, Subcomisión de; Investigación, Subcomisión de; Cefen, Grupo de Trabajo Seguimiento de Alto Riesgo; Expertos,

doi:10.5546/aap.2016.84

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Palivizumab was reported to reduce by 55% RSV related hospitalization in preterm infants with chronic lung disease [ 57 ] and in infants with hemodynamically significant congenital heart disease [ 58 ]. Palivizumab prophylaxis is effective, but it is highly expensive; for this reason its use for prevention of severe RSV infections in high risk pediatric populations is limited to the developed countries, where its use is regulated by guidelines in several countries (i.e., USA, UK, Canada, Italy, Scotland, Spain, Japan, Argentina) [ 8 , 59 , 60 , 61 , 62 , 63 , 64 ].…”

Section: State Of the Art For Active And Passive Prophylaxis Againmentioning

confidence: 99%

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Vandini

Biagi

Lanari

2017

IJMS

122

112

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most common causes of infant viral death worldwide, with infection typically occurring as recurrent seasonal epidemics. There are two major RSV subtypes, A and B, and multiple genotypes, which can coexist during RSV epidemic season every year and result in different disease severity. Recently, new RSV genomic sequences and analysis of RSV genotypes have provided important data for understanding RSV pathogenesis. Novel RSV strains do spread rapidly and widely, and a knowledge of viral strain-specific phenotypes may be important in order to include the more virulent strains in future therapeutical options and vaccine development. Here we summarize recent literature exploring genetic and molecular aspects related to RSV infection, their impact on the clinical course of the disease and their potential utility in the development of safe and effective preventive and therapeutic strategies.

show abstract

Section: State Of the Art For Active And Passive Prophylaxis Againmentioning

confidence: 99%

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Vandini

Biagi

Lanari

2017

IJMS

122

112

View full text Add to dashboard Cite

show abstract

“…Las contraindicaciones para la administración de Palivizumab consisten en pacientes con trombocitopenia y trastornos de coagulación (Fernández Jonusas et al, 2016); mientras que como efectos adversos se señalan casos de anafilaxia e hi-persensibilidad grave (Chen et al, 2015). Ante lo expuesto, es conveniente que las pacientes gestantes de alto riesgo con probabilidad de embarazo pretérmino o cuya resolución ocurra en la estación del Virus Sincitial Respiratorio, analizar la importancia de que a su hijo se le administre Palivizumab para prevenir infecciones respiratorias graves.…”

Section: Resultados Y Discusiónunclassified

Palivizumab en la prevención primaria de infecciones respiratorias graves por Virus Sincitial Respiratorio

Durán Ramírez

2023

Rev. Div. Cien.

View full text Add to dashboard Cite

PROBLEMA: El Virus Sincitial Respiratorio (VSR) causa infecciones respiratorias graves en niños, especialmente, en aquellos menores de 2 años, prematuros y con problemas cardíacos o pulmonares. Además, es potencialmente mortal en pacientes de alto riesgo. OBJETIVO: Describir la utilidad del Palivizumab en la prevención de infecciones respiratorias graves por el Virus Sincitial Respiratorio en pacientes pediátricos de alto riesgo. MÉTODO: Se realizó una investigación monográfica de carácter documental que indagó en la literatura y evidencia sobre el Palivizumab. RESULTADOS: La aplicación de Palivizumab en la prevención de infecciones respiratorias graves por el Virus Sincitial Respiratorio acciona en la protección de los pacientes más vulnerables, como los pacientes prematuros de 32 a 35 semanas de gestación asociados con algún factor de riesgo y nacidos en la estación del VSR. La dosis inicial recomendada de Palivizumab para la prevención de la enfermedad respiratoria grave causada por el Virus Sincitial Respiratorio es de 15 miligramos por kilogramo de peso del paciente. CONCLUSIÓN: El Virus Sincitial Respiratorio es un problema de salud importante en niños pequeños. Se desarrolló el anticuerpo Palivizumab para prevenir infecciones graves en niños con ciertos factores de riesgo, como los prematuros y los que tienen problemas cardíacos. Asimismo, reduce las hospitalizaciones y la mortalidad en pacientes de alto riesgo, y es la única forma de prevenir estas enfermedades respiratorias graves en estos pacientes.

show abstract

Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis

Ciapponi,

Palermo,

Sandoval

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundRespiratory Syncytial Virus (RSV) is a common cause of lower respiratory tract infections (LRTI) and hospitalization worldwide. The impact of RSV in Latin America and the Caribbean (LAC) including expensive treatment options, such as palivizumab, have been extensively discussed. However, publications on the impact of RSV disease burden in the region are scarce. This systematic review aimed to determine the incidence and prevalence of RSV in LAC by age and RSV subtype.MethodsWe conducted a systematic review following Cochrane methods to evaluate the disease burden of RSV in LAC countries. We searched studies from January 2012 to January 2023 in literature databases and grey literature without language restrictions. We included guidelines, observational, economic, and surveillance studies from LAC countries. Pairs of reviewers independently selected, and extracted data from included studies. The risk of bias was assessed using the Study Quality Assessment Tools (NHLBI) and AGREE-II. We performed proportion meta-analyses using methods to stabilize the variance. The protocol was registered in PROSPERO (CRD42023393731).ResultsWe included 156 studies, mainly from Brazil (25%), Colombia (14.5%), and Argentina (13.8%), as well as four clinical practice guidelines. Most studies were cross-sectional (76.9%) and were classified as low risk of bias (52.6%). The majority included inpatients (85.6%), pediatric (73.7%), and normal-risk patients (67.1%). The highest pooled prevalence was estimated in patients <1 year old (58%), with type A and B prevalence of 52 and 34%, respectively. The RSV-LRTI incidence was 15/100 symptomatic infants aged <2 years old, and the ICU admission was 42%. The RSV-LRTI lethality was 0.6, 3% in patients aged <2 and 0–5 years old, respectively, and 23% among >65 years old high-risk patients. The identified guidelines lack methodological rigor and have limitations in their applicability. The seasonality was more evident in South America than in Central America and The Caribbean, with a clear gap during the pandemic.ConclusionThis is the most exhaustive and updated body of evidence describing a significant burden of RSV in LAC, particularly at the extremes of life, and its seasonality patterns. Our findings could contribute could contribute facilitating effective prevention and treatment strategies for this significant public health problem.Systematic review registrationPROSPERO CRD UK (registration number: CRD42023393731).

show abstract

Recomendaciones sobre el uso de palivizumab. Actualización 2015

Cited by 4 publications

References 6 publications

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Palivizumab en la prevención primaria de infecciones respiratorias graves por Virus Sincitial Respiratorio

Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis

Contact Info

Product

Resources

About